Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 40 Results

Title
Intervention Indication Therapeutic Area Year Actions
bb2121 for Relapsed and Refractory Multiple Myeloma Idecabtagene vicleucel (Ide-cel; bb2121) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Belantamab mafodotin for relapsed / refractory multiple myeloma – Fourth line Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
Belantamab mafodotin for treating relapsed or refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belantamab mafodotin with bortezomib and dexamethasone for previously treated relapsed/refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated relapsed/refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Carfilzomib in addition to daratumumab and dexamethasone for relapsed and/or refractory multiple myeloma Carfilzomib (Kyprolis; ONO-7057) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
Ciltacabtagene autoleucel for relapsed and refractory multiple myeloma Ciltacabtagene Autoleucel (JNJ-68284528; LCAR-B38M CAR-T cell therapy; LCAR-B38M; JNJ 4528) Multiple myeloma (MM) Haematological Cancer and Lymphomas , Haematology 2021 View  |  Download
Daratumumab (Darzalex) with lenalidomide and dexamethasone for multiple myeloma – first line Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2017 View  |  Download
Daratumumab (subcutaneous injection) for multiple myeloma Daratumumab (Darzalex; JNJ-54767414) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
Daratumumab for the treating high-risk smouldering multiple myeloma Daratumumab (Darzalex; JNJ-54767414) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
1 2 3 4
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications